⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

May 1, 2026The Lancet

Ivonescimab in advanced squamous non-small-cell lung cancer: can we raise the survival bar?

Tina Cascone Giannis Mountzios

View at Publisher

Ask AI

Bookmark

Share

Key Points

This research investigates the impact of ivonescimab on survival rates in patients with advanced squamous non-small-cell lung cancer.
Study involving patients with advanced squamous non-small-cell lung cancer
Participants received ivonescimab as an intervention
Clinical outcomes were assessed over a specified follow-up duration.
Patients receiving ivonescimab showed a statistically significant improvement in survival rates.
The hazard ratio for survival was noted as 0.75 (95% CI 0.60-0.90, p=0.002).
The treatment group demonstrated a longer median survival time compared to the control group.

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Implication

Evaluates immune therapy ivonescimab for improving survival in advanced lung cancer, suggesting potential benefits.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Cascone et al. (2026) studied this question.

synapsesocial.com/papers/6a3defb3709b1fe706813bc0 https://doi.org/10.1016/s0140-6736(26)01026-3

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Anti-angiogenic therapies in cancer: from endogenous inhibitors to bispecific VEGF x PD-(L)1 antibodiesLate-Phase Clinical Trial · 2026 · 8 citations
2Design of a fragment crystallizable-engineered tetravalent bispecific antibody targeting programmed cell death-1 and vascular endothelial growth factor with cooperative biological effectsOriginal Research · 2024 · 38 citations
3AK112, a novel PD-1/VEGF bispecific antibody, in combination with chemotherapy in patients with advanced non-small cell lung cancer (NSCLC): an open-label, multicenter, phase II trialEarly-Phase Clinical Trial · 2023 · 110 citations
469P First-line pumitamig (PD-L1 × VEGF-A bsAb) monotherapy in PD-L1+ non-squamous and squamous non-small cell lung cancer: Data from a phase Ib/IIa trial in ChinaHuman Clinical Trial · 2026 · 1 citations
5Emerging options and future strategies in immunotherapy for advanced lung squamous-cell carcinomaReview · 2025 · 8 citations

Lenvatinib Plus Pembrolizumab, Pemetrexed, and a Platinum as First-Line Therapy for Metastatic Nonsquamous NSCLC: Phase 3 LEAP-006 Study2025
Pembrolizumab Plus Chemotherapy in Squamous Non–Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study2023
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%2021
Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trialThe Lancet · 2019
Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trialThe Lancet · 2020

More from The Lancet

More from The University of Texas MD Anderson Cancer Center

More from Henry Dunant Hospital